Clinical trial
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)…
NCT00090207 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00090207 |
|---|---|
| Title | Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED) |
| Official title | A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Safety, Tolerability and Efficacy of Aprepitant Regimen Compared to Ondansetron Regimen for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With High Dose… |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Nausea, Vomiting |
| Intervention type | Drug |
| Interventions | MK0869, aprepitant / Duration of Treatment: 3 days, Comparator: ondansetron / Duration of Treatment: 4 days |
| Enrollment | 477 |
| Start date | Jan 13, 2004 |
| Primary completion | Sep 30, 2004 |
| Completion | Sep 30, 2004 |
| First posted | Aug 27, 2004 |
| Last update posted | Apr 24, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: